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ABSTRACT
Acute respiratory tract infections (ARTIs) are a leading cause of morbidity and mortality in children
worldwide, but the aetiology of many ARTIs is still unknown. In 2001, researchers in The Netherlands
reported the discovery of a previously unidentiﬁed pathogen called human metapneumovirus (hMPV).
Since its initial description, hMPV has been associated with ARTI in Europe (Italy, France, Spain, the
UK, Germany, Denmark, Finland and Norway), America (the USA, Canada, Argentina and Brazil), Asia
(India, Japan, China and Singapore), Australia and South Africa in individuals of all ages. The incidence
of infection varies from 1.5% to 25%, indicating that hMPV is a ubiquitous virus with a worldwide
distribution. hMPV seems to play an important role as a cause of paediatric upper and lower respiratory
tract infection, with similar, but not identical, epidemiological and clinical features to those of
respiratory syncytial virus and inﬂuenza virus. Moreover, the socio-economic impact of hMPV-infected
children on their families seems to be considerable, which suggests that, like inﬂuenza virus, hMPV
infection may be a substantial public health problem for the community. It may be associated with
signiﬁcant morbidity and mortality in pre-term infants and children with underlying clinical conditions,
although more adequately controlled studies are needed to conﬁrm its importance in such patients.
Many fundamental questions concerning the pathogenesis of hMPV disease and the host’s speciﬁc
immune response remain to be answered. Further studies are also required to properly deﬁne hMPV
diagnosis, treatment and prevention strategies.
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INTRODUCTION
Acute respiratory tract infections (ARTIs) are a
leading cause of morbidity and mortality in
children worldwide [1,2]. A variety of viruses,
including inﬂuenza viruses, respiratory syncytial
virus (RSV), picornaviruses, coronaviruses, para-
inﬂuenza viruses and adenovirus, have been
associated with different respiratory syndromes
in all age groups [3,4]. However, the aetiology of a
large number of ARTIs is still unknown.
Although diagnostic methods may be inadequate,
this suggests that other respiratory pathogens
may remain to be identiﬁed.
During recent years, emerging virus infections
that are probably associated with anthropogenic,
social and environmental changes have been
reported in humans and animals [3,5]. In 2001,
researchers in The Netherlands reported the
isolation of a previously unidentiﬁed RNA virus
from children and adults with ARTI [6]. On the
basis of morphological, biochemical and genetic
analyses, the new virus seemed to be related
closely to avian pneumovirus C, which at that
time was the sole member of the Metapneumovirus
genus, and which was the aetiological agent of an
upper respiratory tract disease in turkeys and
other birds [7–10]. The new virus was therefore
classiﬁed as the ﬁrst member of the Metapneumo-
virus genus of the Pneumovirinae sub-family of
the Paramyxoviridae family that was capable of
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infecting humans, and was designated human
metapneumovirus (hMPV) [7–10]. hMPV differs
from the pneumoviruses (such as RSV), which
also belong to the Pneumovirinae sub-family, in
that it lacks two non-structural proteins and has a
slightly different gene order [7–10]. Genotyping
studies have determined that hMPV strains
can be classiﬁed into two main lineages and four
sub-lineages, named A1, A2, B1 and B2 [11].
Nucleotide sequence variation between hMPV
types A and B is 11.8–47.7%, whereas that
between the genotypes within each lineage is less
[11].
EPIDEMIOLOGY
Since its initial description in 2001, hMPV has been
isolated from individuals of all ages with ARTI
in Europe (Italy, France, Spain, the UK, Germany,
Denmark, Finland and Norway), America (the
USA, Canada, Argentina and Brazil), Asia (India,
Japan, China and Singapore), Australia and South
Africa [7,12–20]. The incidence of infection in
different studies varies from 1.5% to 25%, thus
indicating that hMPV is a ubiquitous virus with a
worldwide distribution [12–20]. It is interesting to
note that detection rates of hMPV have generally
been higher in retrospective studies than in pros-
pective studies, an observation consistent with a
degree of selection bias. This indicates that large
prospective studies are needed in order to clarify
the role of hMPV in various clinical conditions.
The few seroprevalence surveys, from The
Netherlands, Japan and Israel, have demonstrated
that virtually all children are infected by the age of
5–10 years, which indicates that hMPV infection
is acquired early in life [6,10]. However, as the
range of antibody titres measured by immuno-
ﬂuorescence assays was higher in individuals
aged >2 years than in children aged 6–24 months,
it is possible that there is a booster effect as a
consequence of re-infection with the same or a
closely related virus. In addition, studies of sam-
ples collected previously have shown that hMPV
is not a new pathogen, with serological evidence
of human infection dating from 1958 in The
Netherlands, and virus isolation during the last
10–20 years in Europe and Canada [7–10]. These
ﬁndings suggest that hMPV has been in circula-
tion for a long period, but has been recognised
only recently because of the development of new
diagnostic methods.
Surveys have indicated that hMPV has a
seasonal distribution similar to that of RSV and
inﬂuenza viruses, although the greatest number
of hMPV infections are usually diagnosed at the
end of winter or in early spring [12–22]. It has also
been demonstrated that different hMPV geno-
types may co-circulate in the population during a
single year [20,23–25]. However, further studies
over multiple years are needed to clarify the
seasonal nature of hMPV infection and the quan-
titative importance of the different genotypes.
The similar seasonal distribution of several
other respiratory virus infections may result in
coinfection with hMPV and other respiratory
viruses, but the role that hMPV plays as a
co-pathogen is still not understood completely.
Thus, it is not known whether dual infection by
hMPV and RSV is associated with a more severe
disease than that observed when a single virus is
the aetiological agent. Greensill et al. [26] detected
hMPV in 70% of infants with RSV bronchiolitis
who required admission to a paediatric intensive
care unit for ventilatory support, thus suggesting
that hMPV may inﬂuence the severity of RSV
disease. Similarly, Semple et al. [27] observed that
dual infection with hMPV and RSV confers a ten-
fold increase in the relative risk of admission to a
paediatric intensive care unit for mechanical
ventilation. Other recent data support this hypo-
thesis, at least for children aged <3 years [28]. In
contrast with these ﬁndings, but in agreement
with other reports [14,29,30], there was no evi-
dence of increased disease severity in a small
group of children coinfected with hMPV and RSV
or inﬂuenza viruses [17]. hMPV has also been
identiﬁed in patients with SARS in Canada and
Hong Kong [31,32], but probably did not increase
the pathogenicity of the novel coronavirus
identiﬁed as the cause of SARS. However, the
possibility of coinfection may lead to an under-
estimation of the percentage of hMPV-positive
samples identiﬁed in studies in which only
samples negative for other respiratory viruses
are tested. This means that all clinical samples
(not just samples found to be negative for other
viruses) must be tested in order to clarify further
the epidemiology of hMPV infections.
The quantitative importance of hMPV in child-
ren with underlying disease also requires clar-
iﬁcation. Van den Hoogen et al. [33] found that
most hMPV-positive patients aged 5–65 years had
an underlying disease such as cystic ﬁbrosis, or
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had received immunotherapy, and other studies
found that 25–50% of hMPV-positive patients had
an underlying disease [7,10,34]. In contrast, it has
also been reported that hMPV is a frequent cause
of ARTIs in otherwise healthy children, but has a
marginal quantitative impact on patients with
chronic underlying conditions [17]. Large-scale
studies over a long period should reveal the true
incidence of hMPV infections among patients
with underlying diseases. Furthermore, as a case
of life-threatening hMPV pneumonia requiring
extracorporeal membrane oxygenation has been
described in a pre-term infant [35], the import-
ance of considering this newly discovered patho-
gen as a possible cause of pneumonia in neonates
should be emphasised.
PATHOLOGY
In experimental animals, hMPV infection is asso-
ciated with airway epithelial cell changes and
increased inﬂammatory cell inﬁltrates, predomin-
antly mononuclear cells, in the lung interstitium
[36–39]. In addition, hMPV infection causes
increased myoﬁbroblast thickening adjacent to
the airway epithelium and staining of cellular
debris [36]. Moreover, like RSV, hMPV can persist
for several weeks in the lungs, despite an estab-
lished immune response, suggesting that this
virus uses speciﬁc strategies to overcome host
defences [36].
Data regarding the pathology of hMPV in
humans are scarce, and have mostly been collect-
ed for individuals with underlying lung disease
[10]. Specimens obtained by bronchoalveolar
lavage within 4 days of the identiﬁcation of hMPV
in the nasal secretions of children with an acute
episode of respiratory infection have demonstrat-
ed that hMPV affects primarily airway epithelium
[40]. Infection of the airway epithelial cells
results in cell degeneration and ⁄ or necrosis, with
ciliacytophthoria and round, red cytoplasmic
inclusions on a background of haemosiderin-
laden macrophages, abundant neutrophils and
prominent mucus [40]. These ﬁndings, especially
the red cytoplasmic inclusions, are similar to
those seen in infections by RSV, parainﬂuenza
viruses and measles virus. Lung biopsies, per-
formed at least 1 month after a positive hMPV
nasal assay, have shown that later stages of
the disease caused by hMPV include expansion
of peribronchiolar lymphoid tissue, squamous
metaplasia, haemosiderin and accumulation of
intra-alveolar foamy macrophages [40]. These
features indicate chronic ⁄healing airway inﬂam-
mation, with a degree of concomitant airway
obstruction and impairment of the mucociliary
escalator, and correlate well with the bronchiolitis
and wheezing noted clinically in patients with
hMPV infection.
CLINICAL MANIFESTATIONS
hMPV seems to be an important respiratory
pathogen that causes both upper and lower
respiratory tract infections in children [7–18],
who, unlike adults, are rarely asymptomatic,
although most reports are biased toward descrip-
tions of the most severe symptoms in hospitalised
subjects. The fact that most severe cases are found
in paediatric patients suggests that naturally
acquired infection induces partial protection
against the disease. However, it should be empha-
sised that there is no cross-protection among the
different virus strains. A recent report has des-
cribed a child who suffered from two episodes of
hMPV infection during a 1-month period, each
caused by a different strain [41]. Moreover, the
degree of severity seems to be related not only to
age, but also to the strain causing the infection,
with a possible link between the A2 strain, which
is the most frequent, and severe disease [10].
Diagnosis of hMPV infection may be made on
the basis of signs and symptoms, ranging from
rhinopharyngitis to bronchitis and pneumonia,
and some patients may be admitted to intensive
care units [7–10,21,42]. Table 1 summarises the
Table 1. Clinical characteristics and outcomes among
children seen for acute respiratory infection in an emer-
gency department, grouped by virus RNA detection
Characteristics
hMPV-positive
(n = 41)
RSV-positive
(n = 117)
Inﬂuenza-positive
(n = 209)
Clinical presentation
Common cold, no. (%) 3 (7.3) 20 (17.1) 43 (20.6)
Pharyngitis, no. (%) 11 (26.8) 20 (17.1) 73 (34.9)
Acute otitis media, no. (%) 5 (12.2) 10 (8.5) 34 (16.3)
Croup, no. (%) 3 (7.3) 4 (3.4) 7 (3.3)
Acute bronchitis, no. (%) 4 (9.8) 15 (12.8) 20 (9.6)
Wheezing, no. (%) 10 (24.4)a 30 (25.7)a 14 (6.7)
Pneumonia, no. (%) 5 (12.2) 18 (15.4) 18 (8.6)
Clinical outcome
Hospitalisation, no. (%) 2 (4.8) 16 (13.7) 11 (5.3)
School absence,
median days (range)
10 (3–15) 10 (3–12) 12 (5–15)
ap < 0.0001 vs. inﬂuenza-positive children; no other statistically signiﬁcant
differences.
hMPV, human metapneumovirus; RSV, respiratory syncytial virus.
Adapted from Principi et al. [16].
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clinical data for a group of children seen in an
emergency department for acute respiratory
infection, grouped according to virus diagnosis.
In this population, hMPV caused signs and
symptoms that sometimes resembled those of
RSV infection (bronchiolitis, asthma exacerbation
and pneumonia) and sometimes those of inﬂu-
enza (fever and upper respiratory tract infection)
[16]. Boivin et al. [34] also reported that the
clinical presentation of hMPV is similar to that
of other common winter virus infections. hMPV
has also been associated with febrile seizures,
rash, diarrhoea, an enlarged liver, and altered
liver function test results (Table 2) [13].
Several studies have indicated that, like RSV,
hMPV may induce airway alterations and may be
related to the onset and exacerbation of childhood
asthma. Two successive studies by Jartti et al.
[15,43] detected hMPV in 10 ⁄ 132 (8%) and 12 ⁄ 293
(4%) children hospitalised for acute expiratory
wheezing, which suggests that hMPV may trigger
this disease [15,43]. Our own study found that
wheezing was diagnosed in 25.7% of children
with hMPV, and in 23.4% of those with RSV
infection [17]. However, the fact that hMPV-
positive children are older than children who
are RSV-positive may explain why, when wheez-
ing is diagnosed, asthma exacerbation is more
common in the former and bronchiolitis in the
latter, and why hMPV-positive children have less
severe disease, as demonstrated by the lower
frequency of hospitalisation. Nevertheless, pre-
liminary results concerning the association
between asthma and hMPV infections warrant
further research, not least because asthma is a
difﬁcult clinical diagnosis to make in children
aged <2 years.
The pathogenesis of hMPV disease also
requires further clariﬁcation, since the results of
different studies are contradictory. In children
who were positive for hMPV, Jartti et al. [43]
found two chemokines that have been linked to
RSV disease, namely interleukin-8, a chemotactic
factor mainly for neutrophils, and RANTES
(regulated upon activation, normal T-cell
expressed and secreted), a chemotactic factor for
eosinophils. In comparison to children with RSV
infection, the hMPV-positive children had lower
concentrations of RANTES and higher concentra-
tions of interleukin-8 in their respiratory secre-
tions [43]. In contrast, Laham et al. [44] found that
although both hMPV and RSV were associated
with rhinorrhoea, cough and wheezing, hMPV
elicited signiﬁcantly lower levels of respiratory
inﬂammatory cytokines than did RSV. It is,
therefore, not known whether hMPV and RSV
share a common pathogenic mechanism or cause
disease via different mechanisms.
Although the available data suggest that hMPV
mostly causes mild disease in otherwise healthy
children, the question of whether hMPV may
cause severe problems in children with underly-
ing conditions requires further clariﬁcation.
hMPV was the only pathogen detected in two
patients with acute lymphoblastic leukaemia and
ARTI who subsequently died (aged 7 months and
<5 years, respectively) [45,46]. Although there
was no pathological examination in these cases,
that fact that no other pathogens were identiﬁed
suggests that hMPV infection was the cause of
death. In agreement with these observations, Van
den Hoogen et al. [33] found that hMPV-positive
patients aged >5 years had underlying diseases
and presented with more severe clinical signs
than those generally observed in younger
patients. However, a separate study showed that
a child aged 5 years with a diagnosis of acute
lymphoblastic leukaemia who was infected with
hMPV recovered uneventfully [13]. Although
studies of immunocompromised individuals have
so far been relatively small, they seem to show
that the impact of hMPV is similar to that of RSV
and inﬂuenza virus infections.
Table 2. Characteristics of 32 children admitted with
human metapneumovirus (hMPV) infection compared to
age-matched controls with respiratory syncytial virus
(RSV) or inﬂuenza A infection
Characteristics
hMPV
No. positive ⁄
total
(%)
RSV
No. positive ⁄
total
(%)
Inﬂuenza A
No. positive ⁄
total
(%)
Inﬂuenza-like illness
in family contact
10 ⁄ 19 (52.6) 7 ⁄ 29 (24.1) 19 ⁄ 24 (79.1)
Febrile seizure 5 ⁄ 32 (15.6) 1 ⁄ 32 (3.1) 3 ⁄ 32 (9.4)
Congested pharynx 12 ⁄ 32 (37.5) 11 ⁄ 32 (34.4) 11 ⁄ 32 (34.4)
Rash 4 ⁄ 32 (12.5) 1 ⁄ 32 (3.1) 4 ⁄ 32 (12.5)
Enlarged liver 2 ⁄ 32 (6.3) 0 ⁄ 32 (0.0) 4 ⁄ 32 (12.5)
Otitis media 4 ⁄ 32 (12.5) 0 ⁄ 32 (0.0) 0 ⁄ 32 (0.0)
Diarrhoea 2 ⁄ 32 (6.3) 1 ⁄ 32 (3.1) 3 ⁄ 32 (9.4)
Crepitations 18 ⁄ 32 (56.3)a 14 ⁄ 32 (43.8)a 3 ⁄ 32 (9.4)
Wheezing 9 ⁄ 32 (28.1)a 12 ⁄ 32 (37.5)a 2 ⁄ 32 (6.3)
Asthma exacerbation 6 ⁄ 32 (18.8) 2 ⁄ 32 (6.3) 2 ⁄ 32 (6.3)
Acute bronchiolitis 3 ⁄ 32 (9.4) 10 ⁄ 32 (31.3) 0 ⁄ 32 (0.0)
Pneumonia 12 ⁄ 32 (37.5)a 5 ⁄ 32 (15.6)a 1 ⁄ 32 (3.1)
Abnormal chest X-ray 17 ⁄ 25 (68.0)a 11 ⁄ 18 (61.1)a 1 ⁄ 17 (5.9)
Lymphopenia (£1.5 · 109 ⁄L) 9 ⁄ 31 (29) 2 ⁄ 27 (7.4) 12 ⁄ 29 (41.4)
Neutropenia (ANC <1 · 109 ⁄L) 2 ⁄ 31 (6.5) 0 ⁄ 27 (0.0) 4 ⁄ 29 (13.8)
Elevated transaminase 2 ⁄ 15 (13.3) 0 ⁄ 5 (0.0) 3 ⁄ 11 (27.3)
ap < 0.05 vs. inﬂuenza A.
ANC, absolute neutrophils count.
Adapted from Peiris et al. [13].
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Few data are available concerning the socio-
economic impact of hMPV infection on children
and their households. It was reported that the
household contacts of hMPV-positive children, as
well as those of inﬂuenza-positive children, fell ill
signiﬁcantly more frequently, required more
medical visits, received more anti-pyretic pre-
scriptions, and were also absent more frequently
from work or school than those of RSV-positive
children (Table 3) [17]. These ﬁndings show that
hMPV infection in children may considerably
affect their families.
The clinical features described for hMPV dis-
ease are based on studies of small numbers of
patients. Collectively, the available data indicate
that the clinical presentation of hMPV is similar to
that of RSV and inﬂuenza. Socio-economically,
the impact of childhood hMPV infection on
children and their families seems to be similar
to that of inﬂuenza viruses, and signiﬁcantly
greater than that of RSV. Further clinical studies
are needed to elucidate the quantitative and
qualitative characteristics of hMPV infection,
and the groups at risk for severe complications.
DIAGNOSIS
Because hMPV replicates poorly in the conven-
tional cell cultures used for the diagnosis of
respiratory viruses, it is relatively difﬁcult to
isolate and has probably circulated unreported for
some considerable time. Most studies have only
detected reliable cytopathic effects in tertiary
monkey kidney (tMK) and LLC-MK2 cells
[6–10]. The cytopathic effect varies, with some
strains inducing RSV-like syncytia formation, and
others causing focal rounding and cell destruc-
tion. More cell lines have been explored following
the original isolation of hMPV, and some labor-
atories now use Vero or human laryngeal carci-
noma (HEp-2) cells successfully [7–10]. In the
absence of commercially available antibodies, the
cytopathic effect of hMPV can be conﬁrmed by
using RT-PCR to test infected supernatants.
RT-PCR has become the method of choice for
the diagnosis of acute hMPV infection, because of
the unavailability of rapid antigen detection tests,
and the slow and restrictive growth of the virus
[7–10]. Most PCR protocols published to date rely
on ampliﬁcation of the L (major polymerase
subunit), N (nucleoprotein), or F (fusion protein)
gene, using primer sequences derived mainly
from the prototype strain 001 from The Nether-
lands (GenBank accession number AF371337)
[47–49]. Because of the existence of two hMPV
lineages showing signiﬁcant genetic variability,
hMPV detection may be underestimated when
inappropriate primers are used. New rapid and
sensitive hMPV assays, based on real-time PCR,
allow ampliﬁcation and detection of hMPV in
£2 h [47–49]. In comparison with conventional
RT-PCR, real-time RT-PCR is more sensitive,
faster and more cost-effective, and may thus be
the best means of detecting hMPV routinely.
Serological tests only permit a retrospective
diagnosis and, because infection is almost uni-
versal in childhood, seroconversion or a ‡4-fold
increase in antibody titres must be demonstrated
to conﬁrm recent infection [7–10,48]. A recent
serological survey of hMPV was based on use of
a novel ELISA using hMPV-fusion protein
expressed in recombinant vescicular stomatitis
virus [49]. Large serological surveys using this
and other simple ELISAs are needed to permit a
better understanding of the worldwide epidemi-
ology of hMPV infection. Detection of hMPV
antigens in nasopharyngeal secretions by an
immunoﬂuorescent antibody test has also pro-
vided interesting results [50,51].
TREATMENT AND PREVENTION
No treatment is registered currently and no
speciﬁc prevention procedures are recommended
Table 3. Clinical and socio-economic impact of different
virus infections among the household contacts of the
children in whom a single infectious agent was demon-
strated
Characteristics
Households of
hMPV-positive
children
(n = 128)
Households of
RSV-positive
children
(n = 507)
Households of
inﬂuenza-positive
children
(n = 806)
Disease similar to that of
the infected child, no. (%)
16 (12.5)a 24 (4.7) 78 (9.7)a
Additional medical
visits, no. (%)
16 (12.5)b 16 (3.2) 78 (9.7)b
Anti-pyretic
prescriptions, no. (%)
14 (10.9)a 18 (3.6) 104 (12.9)b
Antibiotic
prescriptions, no. (%)
6 (4.7) 11 (2.2) 36 (4.5)
Hospitalisation, no. (%) 0 0 3 (0.4)
Lost working days,
median (range)
4 (2–10)a 2.5 (2–7) 4 (1–10)a
Lost school days,
median (range)
4 (3–15)a 2 (2–4) 5 (1–15)a
ap <0.05 and bp <0.0001 vs. households of RSV-positive children; no other
statistically signiﬁcant differences.
hMPV, human metapneumovirus; RSV, respiratory syncytial virus.
Adapted from Bosis et al. [17].
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for the management of hMPV infection. Ribavirin
and a polyclonal intravenous immunoglobulin
preparation have been found to have similar
in-vitro antiviral activity against both hMPV and
RSV [52], but clinical studies are required to
conﬁrm these observations. However, given the
well-known limitations of these medications
(i.e., severe adverse events, difﬁcult administra-
tion and high costs), they should be used with
caution and probably considered only for treating
immunocompromised patients with severe hMPV
disease, as in the case of RSV infection. Further-
more, high-titred intravenous immunoglobulin
preparations active against hMPV could be used
in patients with severe disease [9].
Studies on the development of a speciﬁc vac-
cine are currently in progress in experimental
animals. Biacchesi et al. [25] were able to generate
recombinant hMPVs lacking some genes that
were at least 40-fold and 600-fold, respectively,
restricted in replication in the lower and upper
respiratory tract compared with wild-type recom-
binant hMPV [25]. However, many more studies
are required before there is the possibility of an
effective and safe vaccine for humans.
CONCLUSIONS
The recent identiﬁcation of a presumably old
virus pathogen is an exciting development in the
ﬁeld of respiratory viruses. Considering the avail-
able studies as a whole, hMPV appears to play an
important role as a cause of paediatric upper and
lower respiratory tract infection. In general, many
of the epidemiological and clinical features of
hMPV infection seem to be similar to those of RSV
and inﬂuenza, although some differences have
been noted [7–20]. Moreover, the socio-economic
impact of hMPV-infected children on their fam-
ilies seems to be signiﬁcant, suggesting that, like
inﬂuenza, hMPV infection may be a substantial
public health problem for the community [16,17].
hMPV can cause morbidity and mortality in
pre-term infants [35] and children with underly-
ing clinical conditions, including immunocom-
promised patients [33,34,45,46], although further
adequately controlled studies are needed to
conﬁrm this.
Many fundamental questions concerning the
pathogenesis of hMPV disease and the host’s
speciﬁc immune response remain to be answered.
Further surveillance studies are necessary to
deﬁne the full spectrum of childhood hMPV
infection completely, as well as the risk-factors
associated with severe hMPV disease. At least
two circulating serotypes of hMPV have been
identiﬁed [8,10], and this must be taken into
account when developing diagnostic tests or
measures for prevention and treatment of infec-
tion.
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